The agency alleges CVS’s Caremark, Cigna’s Express Scripts and UnitedHealth’s Optum Rx accepted money from drugmakers in ...
The FTC filed a lawsuit on Friday, alleging three largest pharmacy benefit managers “artificially" inflated the cost of ...
The Federal Trade Commission alleges that pharmacy benefits managers prioritized high rebates from drug makers for insulin over lower prices for consumers, leading to inflated out-of-pocket costs.
In a lawsuit, the FTC accused Optum Rx, Caremark and Express Scripts of creating "a broken rebate system that inflated insulin drug prices, boosting PBM (prescription drug benefit managers) profits at ...
FTC sues top PBMs for inflating insulin prices, accusing them of rigging competition and hurting patients. Legal action also includes GPOs.
The federal government is suing some pharmacy benefit managers over a system of drug rebates that regulators say has made the ...
The Federal Trade Commission (FTC) on Friday sued the three largest pharmacy benefit managers (PBMs) for engaging in alleged ...
PBMs, like Optum Rx, are the key counterweight to pharmaceutical companies’ otherwise unchecked monopoly power to set and raise drug prices.
The FTC said CVS Caremark, Cigna’s Express Scripts, and UnitedHealth’s OptumRx profit at the expense of patients forced to ...
Cigna may have the edge with smaller footprint and focused approach, but all three giants face risks from FTC's lawsuit over inflated insulin prices.
The Federal Trade Commission on Friday sued prescription-drug middlemen owned by CVS Health Corp., Cigna Group and UnitedHealth Group Inc., alleging that they artificially pumped up prices of insulin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback